Literature DB >> 15168958

Management of hyponatremia.

Kian Peng Goh1.   

Abstract

Hyponatremia is an important electrolyte abnormality with the potential for significant morbidity and mortality. Common causes include medications and the syndrome of inappropriate antidiuretic hormone (SIADH) secretion. Hyponatremia can be classified according to the volume status of the patient as hypovolemic, hypervolemic, or euvolemic. Hypervolemic hyponatremia may be caused by congestive heart failure, liver cirrhosis, and renal disease. Differentiating between euvolemia and hypovolemia can be clinically difficult, but a useful investigative aid is measurement of plasma osmolality. Hyponatremia with a high plasma osmolality is caused by hyperglycemia, while a normal plasma osmolality indicates pseudohyponatremia or the post-transurethral prostatic resection syndrome. The urinary sodium concentration helps in diagnosing patients with low plasma osmolality. High urinary sodium concentration in the presence of low plasma osmolality can be caused by renal disorders, endocrine deficiencies, reset osmostat syndrome, SIADH, and medications. Low urinary sodium concentration is caused by severe burns, gastrointestinal losses, and acute water overload. Management includes instituting immediate treatment in patients with acute severe hyponatremia because of the risk of cerebral edema and hyponatremic encephalopathy. In patients with chronic hyponatremia, fluid restriction is the mainstay of treatment, with demeclocycline therapy reserved for use in persistent cases. Rapid correction should be avoided to reduce the risk of central pontine myelinolysis. Loop diuretics are useful in managing edematous hyponatremic states and chronic SIADH. In all instances, identifying the cause of hyponatremia remains an integral part of the treatment plan.

Entities:  

Mesh:

Year:  2004        PMID: 15168958

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  21 in total

1.  Reset osmostat: a rare cause of hyponatraemia.

Authors:  Beatriz Maia Vale; Sofia Morais; Joana Mesquita; Gabriela Mimoso
Journal:  BMJ Case Rep       Date:  2015-06-29

2.  Safety, local tolerability and pharmacokinetics of ceftaroline fosamil administered in a reduced infusion volume.

Authors:  Timi Edeki; Mirjana Kujacic; Helen Broadhurst; Jianguo Li; Maria Sunzel
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

Review 3.  Impact of perioperative hyponatremia in children: A narrative review.

Authors:  Cheme Andersen; Arash Afshari
Journal:  World J Crit Care Med       Date:  2014-11-04

Review 4.  Organic osmolytes in hyponatremia and ammonia toxicity.

Authors:  Jessica Heins; Claudia Zwingmann
Journal:  Metab Brain Dis       Date:  2010-03-02       Impact factor: 3.584

5.  Extracellular glutamine is a critical modulator for regulatory volume increase in human glioma cells.

Authors:  Nola Jean Ernest; Harald Sontheimer
Journal:  Brain Res       Date:  2007-01-30       Impact factor: 3.252

6.  Role of BKbeta1 in Na+ reabsorption by cortical collecting ducts of Na+-deprived mice.

Authors:  P Richard Grimm; Debra L Irsik; Liping Liu; J David Holtzclaw; Steven C Sansom
Journal:  Am J Physiol Renal Physiol       Date:  2009-05-20

Review 7.  Hyponatremia in patients with heart failure.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2013-09-26

Review 8.  Diagnosis and management of hyponatremia in cancer patients.

Authors:  Harry Raftopoulos
Journal:  Support Care Cancer       Date:  2007-08-14       Impact factor: 3.603

Review 9.  Hyponatremia in acute heart failure syndromes: a potential therapeutic target.

Authors:  Filippo Brandimarte; Francesco Fedele; Leonardo De Luca; Gregg C Fonarow; Mihai Gheorghiade
Journal:  Curr Heart Fail Rep       Date:  2007-12

10.  Uncontrolled headache induced by oxcarbazepine.

Authors:  Elcio Juliato Piovesan; Helio Ghizoni Teive; Luciano de Paola; Carlos Eduardo Silvado; Ana Crippa; Vanise Campos Gomes Amaral; Marcos Vinicius Della Colleta; Fabrizio Di Stani; Lineu Cesar Werneck
Journal:  J Headache Pain       Date:  2007-10-23       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.